Educational content only — this is not medical advice. Nothing here is a recommendation to buy, obtain, or use PT-141. Talk to a licensed clinician before making health decisions.
What it is
PT-141 is a heptapeptide synthetic analog of alpha-melanocyte-stimulating hormone. It activates melanocortin receptors in the central nervous system to increase sexual arousal and desire. Unlike sildenafil, it does not primarily act on penile vasculature.
What the evidence shows
Two Phase 3 trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder showed statistically significant improvements in sexual desire and distress with bremelanotide 1.75 mg versus placebo. Onset is rapid, and it is used on demand.
Risks & unknowns
The most common adverse events are nausea, flushing, injection-site reactions, headache, and vomiting. Bremelanotide can cause transient increases in blood pressure and reductions in heart rate; it is contraindicated in uncontrolled hypertension and cardiovascular disease. It can also cause focal skin hyperpigmentation with repeated use.
Legal / regulatory status
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is prescription-only. Use in men or for erectile dysfunction is off-label and not FDA-approved.
